|
[1]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.
|
|
[2]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.
|
|
[3]TRIVEDI PJ, LAMMERS WJ, van BUUREN HR, et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut, 2016, 65 (2) :321-329.
|
|
[4]CARBONE M, MELLS GF, PELLS G, et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J].Gastroenterology, 2013, 144 (3) :560-569.e7.
|
|
[5]CHEUNG A, LAMMERS WJ, HIRSCHFIELD GM, et al.Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis[J].J Hepatol, 2015, 62:s798.
|
|
[6]PRINCE M, CHETWYND A, NEWMAN W, et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology, 2002, 123 (4) :1044-1051.
|
|
[7]de LISO F, MATINATO C, RONCHI M, et al.The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA) -negative PBCpatients:a review of literature[J].Clin Chem Lab Med, 2017.[Epub ahead of print]
|
|
[8]LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology, 2014, 147:1338-1349.
|
|
[9] TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/plateletratio index predicts outcome independent of ursodeoxycholic acid response[J].JHepatol, 2014, 60 (6) :1249-1258.
|
|
[10]NAKAMURA M, KONDO H, MORI T, et al.Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology, 2007, 45 (1) :118-127.
|
|
[11]ZHANG LN, SHI TY, SHI XH, et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study[J].Hepatology, 2013, 58 (1) :264-272.
|
|
[12]FLOREANI A, FRANCESCHET I, CAZZAGON N, et al.Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :192-197.
|
|
[13]BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al.Overlap syndromes:the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J].J Hepatol, 2011, 54 (2) :374-385.
|
|
[14]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:the diagnosis and managementof patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.
|
|
[15]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.
|
|
[16]CARBONE M, SHARP SJ, FLACK S, et al.The UKPBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis[J].Hepatology, 2016, 63 (3) :930-950
|
|
[17]CORPECHOT C, ABENAVOLI L, RABAHI N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology, 2008, 48 (3) :871-877.
|
|
[18]PARES A, CABALLERIA L, RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology, 2006, 130 (3) :715-720.
|
|
[19]CORPECHOT C, CHAZOUILLERES O, POUPON R.Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome[J].J Hepatol, 2011, 55 (6) :1361-1367.
|
|
[20]KUMAGI T, GUINDI M, FISCHER SE, et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol, 2010, 105 (10) :2186-2194.
|
|
[21]TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response[J].JHepatol, 2014, 60 (6) :1249-1258.
|
|
[22]HUET PM, VINCENT C, DESLAURIER J, et al.Portal hypertension and primary biliary cirrhosis:effect of long-term ursodeoxycholic acid treatment[J].Gastroenterology, 2008, 135 (50) :1552-1560.
|
|
[23]KAKUDA Y, HARADA K, SAWADA-KITAMURA S, et al.E-valuation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems[J].Hum Pathol, 2013, 44 (6) :1107-1117.
|
|
[24]WENDUM D, BOELLE PY, BEDOSSA P, et al.Primary biliary cirrhosis:proposal for a new simple histological scoring system[J].Liver Int, 2015, 35 (2) :652-659.
|
|
[25]CORPECHOT C, CARRAT F, POUJOL-ROBERT A, et al.Noninvasive elastography-based assessment ofliver fibrosis progression and prognosis in primary biliary cirrhosis[J].Hepatology, 2012, 56 (1) :198-208.
|
|
[26]FLOREANI A, CAZZAGON N, MARTINES D, et al.Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis[J].Dig Liver Dis, 2011, 43 (11) :887-892
|
|
[27]MAYO M, PARKES J, ADAMS-HUET B, et al.Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay[J].Hepatology, 2008, 48 (5) :1549-1557.
|
|
[28] NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[29]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
|
|
[30]DHANDA A, LEE R, COLLINS P.Is primary biliary cirrhosis a steroid-sensitive autoimme disease?[J].Hepatol Res, 2012, 42 (6) :619-620.
|
|
[31]IWASAKI S, TSUDA K, UETA H, et al.Benzafibrate may have beneficial effect in pre-cirrhotic primary biliary cirrhosis[J].Hepatol Res, 1999, 16 (1) :12-18.
|
|
[32]RUDIC JS, POROPAT G, KRSTIC MN, et al.Bezafibrate for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2012, 1:cd450091.
|
|
[33]GRIGORIAN AY, MARDINI HE, CORPECHOT C, et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2015, 39 (3) :296-306.
|
|
[34]PHILLIPS JR, ANGULO P, PETTERSON T, et al.Fat-soluble vitamin levels in patients with primary biliary cirrhosis[J].Am JGastroenterol, 2001, 96 (9) :2745-2750.
|
|
[35]MAILLETTE de BWL, BEUERS U.Bile salts and cholestasis[J].Dig Liver Dis, 2010, 42 (6) :409-418.
|
|
[36]TRIVEDI PJ, CORPECHOT C, PARES A, et al.Risk stratification in autoimmune cholestatic liver diseases:opportunities for clinicians and trialists[J].Hepatology, 2016, 63 (2) :644-659.
|
|
[37]ADAM R, KARAM V, DELVART V, et al.Evolution of indications and results of liver transplantation in Europe.A report from the European Liver Transplant Registry (ELTR) [J].J Hepatol, 2012, 57 (3) :675-688.
|
|
[38]GAUTAM M, CHERUVATTATH R, BALAN V.Recurrence of autoimmune liver disease after liver transplantation:a systematic review[J].Liver Transpl, 2006, 12 (12) :1813-1824.
|
|
[39]HUBSCHER SG, ELIAS E, BUCKELS JA, et al.Primary biliary cirrhosis.Histological evidence of disease recurrence after liver transplantation[J].J Hepatol, 1993, 18 (2) :173-184.
|
|
[40]BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J].J Hepatol, 2015, 63 (6) :1449-1458.
|
DownLoad: